EARLY Biomarker Panel for Ovarian Cancer Detection
Official title: EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection
Run by Queensland Centre for Gynaecological Cancer · NCT07491081 · Data updated 2026-11-12
This project will test whether different blood collection, storage, and transport methods keep ovarian cancer extracellular vesicle biomarkers stable in postmenopausal people aged 50–74.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 74 Years |
| Sex | Women only |
| Enrollment | 1500 (estimated) |
| Sponsor | Queensland Centre for Gynaecological Cancer Government |
| Locations | 2 sites (Brisbane, Queensland and 1 other locations) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2030 |
| Registry record updated | March 24, 2026 |
| Trial ID | NCT07491081 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are postmenopausal people aged 50–74 without a history of ovarian cancer or bilateral oophorectomy who can provide informed consent and attend a Brisbane collection site.
✕Probably not a fit
People with prior ovarian malignancy, a prior bilateral oophorectomy, those outside the 50–74 age range, or those unable to attend the Queensland collection sites are not eligible and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study will recruit 1,500 postmenopausal participants across Queensland through community groups and the Mater Research Biobank with informed consent. Blood samples will be collected using predefined protocols and processed at collaborating laboratory sites to isolate extracellular vesicles (EVs). The study will systematically vary collection protocols, storage temperatures, transport conditions, and time-to-processing to measure EV biomarker stability. Findings will be used to recommend practical sample-handling procedures for future blood-based ovarian cancer screening efforts.
Why it matters
Potential benefit: If successful, the work could make blood-based ovarian cancer screening more reliable by identifying best practices for sample collection and handling.
How similar studies have gone: Research on extracellular vesicle biomarkers for ovarian cancer is promising but remains largely experimental and has not yet produced widely adopted clinical screening tests.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 50 and 74 years (inclusive). 2. Postmenopausal status, defined as either: 2.1. At least 12 consecutive months of amenorrhoea following natural menopause or hysterectomy, or 2.2. At least 12 months of hormone replacement therapy (HRT) commenced for the management of menopausal symptoms. 3. Signed written informed consent. Exclusion Criteria: 1. History of previous ovarian malignancy. 2. History of bilateral oophorectomy.
Where it's running
-
Mater Misericordiae Ltd
Brisbane, Queensland, Australia Recruiting -
The University of Queensland
Brisbane, Queensland, Australia Recruiting
Study contacts
- Study coordinator: Sara Baniahmadi
- Email: s.baniahmadi@uq.edu.au
- Phone: +61 7 3346 5073
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.